CI Investments Inc. Lowers Stock Holdings in Zoetis Inc. $ZTS

CI Investments Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 3.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 341,911 shares of the company’s stock after selling 11,687 shares during the quarter. CI Investments Inc. owned about 0.08% of Zoetis worth $40,417,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. J. Stern & Co. LLP lifted its stake in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. Norges Bank bought a new position in Zoetis in the 4th quarter valued at $734,425,000. Vanguard Group Inc. boosted its holdings in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Van ECK Associates Corp grew its position in shares of Zoetis by 269.0% during the 4th quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock valued at $300,340,000 after purchasing an additional 1,740,113 shares in the last quarter. Finally, FIL Ltd grew its position in shares of Zoetis by 372.2% during the 4th quarter. FIL Ltd now owns 2,134,404 shares of the company’s stock valued at $268,551,000 after purchasing an additional 1,682,384 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $75.26 on Wednesday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48. The company has a fifty day moving average of $77.29 and a 200-day moving average of $105.18. The stock has a market capitalization of $31.55 billion, a price-to-earnings ratio of 12.48, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is currently 35.16%.

Insider Activity

In related news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ZTS shares. JPMorgan Chase & Co. lowered their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Finally, UBS Group dropped their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $120.83.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Unusual options activity showed traders buying 8,095 call options, well above the normal daily volume of about 5,087, suggesting some investors are positioning for a rebound. MarketBeat options activity report

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.